<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>DURACLON- clonidine hydrochlorideÂ injection, solutionÂ </strong><br>Mylan Institutional LLC<br></p></div>
<h1></h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="id_3e9c09a3-5ae6-4c2b-aa11-7a78ccd66dad"></a><a name="section-1"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">The 500 mcg/mL strength product should be diluted prior to use in an appropriate solution.</span></p>
</div>
<div class="Warning">
<a name="id_3ce4ab61-4ff6-48e0-9920-51704d50c47b"></a><a name="section-1"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">NOTE: Duraclon<span class="Sup">Â®</span> (epidural clonidine) is not recommended for obstetrical, post-partum, or peri-operative <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> management. The risk of <span class="product-label-link" type="condition" conceptid="4311860" conceptname="Hemodynamic instability">hemodynamic instability</span>, especially <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> and <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, from epidural clonidine may be unacceptable in these patients. However, in a rare obstetrical, post-partum or peri-operative patient, potential benefits may outweigh the possible risks.</span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_3a95fac6-ddf9-42d3-b7ac-bdcb8f8dc966"></a><a name="section-1"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Duraclon (clonidine hydrochloride injection) is a centrally-acting analgesic solution for use in continuous epidural infusion devices.</p>
<p>Clonidine Hydrochloride, USP, is an imidazoline derivative and exists as a mesomeric compound. The chemical names are Benzenamine,2,6-dichloro-N-2-imidazolidinylidene monohydrochloride and 2-[(2,6-dichlo-rophenyl)imino]imidazolidine monohydrochloride. The following is the structural formula:</p>
<div class="Figure">
<a name="id315"></a><img alt="Clonidine Hydrochloride Structural Formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=8c126bb8-732a-4949-8754-2f50b5543638&amp;name=e3b05939-069f-4822-8694-b693a044adb3-01.jpg">
</div>
<p>Duraclon (clonidine hydrochloride injection) is supplied as a clear, colorless, preservative-free, pyrogen-free, aqueous sterile solution (pH 5 to 7) in single-dose, 10 mL vials.</p>
<p>Each mL of the 100 mcg/mL (0.1 mg/mL) concentration contains 100 mcg of Clonidine Hydrochloride, USP and 9 mg Sodium Chloride, USP in Water for Injection, USP. Hydrochloric Acid and/or Sodium Hydroxide may have been added for pH adjustment. Each 10 mL vial contains 1 mg (1000 mcg) of clonidine hydrochloride.</p>
<p>Each mL of the 500 mcg/mL (0.5 mg/mL) concentration contains 500 mcg of Clonidine Hydrochloride, USP and 9 mg Sodium Chloride, USP in Water for Injection, USP. Hydrochloric Acid and/or Sodium Hydroxide may have been added for pH adjustment. Each 10 mL vial contains 5 mg (5000 mcg) of clonidine hydrochloride. </p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_a61d4026-7aae-4211-9bb5-332675db4e46"></a><a name="section-2"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First"><span class="Bold"><span class="Italics">Mechanism of Action</span></span></p>
<p>Epidurally administered clonidine produces dose-dependent <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> not antagonized by opiate antagonists. The <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> is limited to the body regions innervated by the spinal segments where analgesic concentrations of clonidine are present. Clonidine is thought to produce <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> at presynaptic and postjunctional alpha-2-adrenoceptors in the spinal cord by preventing <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> signal transmission to the brain.</p>
<p><span class="Bold"><span class="Italics">Pharmacokinetics</span></span></p>
<p>Following a 10 minute intravenous infusion of 300 mcg clonidine HCl to five male volunteers, plasma clonidine levels showed an initial rapid distribution phase (meanÂ±SD t<span class="Sup">1</span>â?„<span class="Sub">2</span>=11Â±9 minutes) followed by a slower elimination phase (t<span class="Sup">1</span>â?„<span class="Sub">2</span>=9Â±2 hours) over 24 hours. Clonidineâ€™s total body clearance (CL) was 219Â±92 mL/min.</p>
<p>Following a 700 mcg clonidine HCl epidural dose given over five minutes to four male and five female volunteers, peak clonidine plasma levels (4.4Â±1.4 ng/mL) were obtained in 19Â±27 minutes. The plasma elimination half-life was determined to be 22Â±15 hours following sample collection for 24 hours. CL was 190Â±70 mL/min. In cerebral spinal fluid (CSF), peak clonidine levels (418Â±255 ng/mL) were achieved in 26Â±11 minutes. The clonidine CSF elimination half-life was 1.3Â±0.5 hours when samples were collected for 6 hours. Compared to men, women had a lower mean plasma clearance, longer mean plasma half-life, and higher mean peak level of clonidine in both plasma and CSF.</p>
<p>In cancer patients who received 14 days of clonidine HCl epidural infusion (rate=30 mcg/hr) plus morphine by patient-controlled <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> (PCA), steady state clonidine plasma concentrations of 2.2Â±1.1 and 2.4Â±1.4 ng/mL were obtained on dosing days 7 and 14, respectively. CL was 279Â±184 and 272Â±163 mL/min on these days. CSF concentrations were not determined in these patients.</p>
<p><span class="Bold"><span class="Italics">Distribution</span></span></p>
<p>Clonidine is highly lipid soluble and readily distributes into extravascular sites including the central nervous system. Clonidineâ€™s volume of distribution is 2.1Â±0.4 L/kg. The binding of clonidine to plasma protein is primarily to albumin and varies between 20 and 40% <span class="Italics">in vitro</span>. Epidurally administered clonidine readily partitions into plasma via the epidural veins and attains systemic concentrations (0.5 - 2.0 ng/mL) that are associated with a hypotensive effect mediated by the central nervous system.</p>
<p><span class="Bold"><span class="Italics">Excretion</span></span></p>
<p>Following an intravenous dose of <span class="Sup">14</span>C-clonidine, 72% of the administered dose was excreted in urine in 96 hours of which 40-50% was unchanged clonidine. Renal clearance for clonidine was determined to be 133Â±66 mL/min. In a study where <span class="Sup">14</span>C-clonidine was given to subjects with varying degrees of kidney function, elimination half-lives varied (17.5 to 41 hours) as a function of creatinine clearance. In subjects undergoing hemodialysis only 5% of body clonidine stores were removed.</p>
<p><span class="Bold"><span class="Italics">Metabolism</span></span></p>
<p>In humans, clonidine metabolism follows minor pathways with the major metabolite, p-hydroxy-clonidine, being present at less than 10% of the concentration of unchanged drug in urine.</p>
<p><span class="Bold"><span class="Italics">Special Populations</span></span></p>
<p>The pharmacokinetics of epidurally administered clonidine has not been studied in the pediatric population or in patients with renal or <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic disease</span>.</p>
<p><span class="Bold"><span class="Italics">Clinical Trials</span></span></p>
<p>In a double-blind, randomized study of cancer patients with severe <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">intractable pain</span> below the C4 dermatome not controlled by morphine, 38 patients were randomized to an epidural infusion of Duraclon plus epidural morphine, whereas 47 subjects received epidural placebo plus epidural morphine. Both groups were allowed rescue doses of epidural morphine. Successful <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span>, defined as a decrease in either morphine use or Visual Analog Score (VAS) <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, was significantly more common with epidural clonidine than placebo (45% vs 21%, p=0.016). Only the subgroup of 36 patients with â€˜â€˜neuropathicâ€™â€™ <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, characterized by the investigator as well-localized, burning, shooting, or electric-like <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in a dermatomal or peripheral nerve distribution had significant <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesic effects</span> relative to placebo in this study.</p>
<p>The most frequent adverse events with clonidine were <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> (45% vs 11% for placebo, p&lt; 0.001), <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">postural hypotension</span> (32% vs 0%, p&lt; 0.001), <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> (13% vs 4%, p=0.234), <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span> (11% vs 2%, p=0.168) and <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span> (13% vs 9%, p=0.505). Both mean blood pressure and heart rate were reduced in the clonidine group. At the conclusion of the two week study period in the clinical trial, all patients were abruptly withdrawn from study drug or placebo. Four patients of the clonidine group suffered <span class="product-label-link" type="condition" conceptid="4221991" conceptname="Rebound hypertension">rebound hypertension</span> upon withdrawal of clonidine; one of these patients suffered a <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">cerebrovascular accident</span>. Asymptomatic <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span> was noted in one clonidine patient.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_23f50cd3-2a58-4861-8561-9633fa1b6760"></a><a name="section-3"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">Duraclon is indicated in combination with opiates for the treatment of severe <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in cancer patients that is not adequately relieved by opioid analgesics alone. Epidural clonidine is more likely to be effective in patients with <span class="product-label-link" type="condition" conceptid="373852" conceptname="Neuralgia">neuropathic pain</span> than somatic or <span class="product-label-link" type="condition" conceptid="4251315" conceptname="Visceral pain">visceral pain</span> (see <span class="Bold"><a href="#i4i_clinical_pharmacology_id_a61d4026-7aae-4211-9bb5-332675db4e46">Clinical Trials</a></span>).</p>
<p>The safety of this drug product has only been established in a highly selected group of cancer patients, and only after an adequate trial of opioid <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span>. Other use is of unproven safety and is not recommended. In a rare patient, the potential benefits may outweigh the known risks (see <span class="Bold"><a href="#i4i_warnings_id_369afbc8-7987-40f9-8113-29f28f9e09b7">WARNINGS</a></span>).</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_cf1653a6-3edb-4c1e-8a0b-c548a11adeb6"></a><a name="section-4"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Duraclon is contraindicated in patients with a history of sensitization or <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> to clonidine. Epidural administration is contraindicated in the presence of an <span class="product-label-link" type="condition" conceptid="4318388" conceptname="Injection site infection">injection site infection</span>, in patients on anticoagulant therapy, and in those with a <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> diathesis. Administration of Duraclon above the C4 dermatome is contraindicated since there are no adequate safety data to support such use (see <span class="Bold"><a href="#i4i_warnings_id_369afbc8-7987-40f9-8113-29f28f9e09b7">WARNINGS</a></span>).</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="i4i_warnings_id_369afbc8-7987-40f9-8113-29f28f9e09b7"></a><a name="section-5"></a><p></p>
<h1>WARNINGS</h1>
<p class="First"><span class="Bold"><span class="Italics">Use in Postoperative or Obstetrical <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">Analgesia</span></span></span></p>
<p>Duraclon (epidural clonidine) is not recommended for obstetrical, post-partum, or peri-operative <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> management. The risk of <span class="product-label-link" type="condition" conceptid="4311860" conceptname="Hemodynamic instability">hemodynamic instability</span>, especially <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> and <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, from epidural clonidine may be unacceptable in these patients.</p>
<p><span class="Bold"><span class="Italics"><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span></span></span></p>
<p>Because severe <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> may follow the administration of clonidine, it should be used with caution in all patients. It is not recommended in most patients with severe cardiovascular disease or in those who are otherwise hemodynamically unstable. The benefit of its administration in these patients should be carefully balanced against the potential risks resulting from <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>.</p>
<p>Vital signs should be monitored frequently, especially during the first few days of epidural clonidine therapy. When clonidine is infused into the upper thoracic spinal segments, more pronounced decreases in the blood pressure may be seen.</p>
<p>Clonidine decreases sympathetic outflow from the central nervous system resulting in decreases in peripheral resistance, renal <span class="product-label-link" type="condition" conceptid="4089490" conceptname="Vascular resistance">vascular resistance</span>, heart rate, and blood pressure. However, in the absence of profound <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, renal blood flow and glomerular filtration rate remain essentially unchanged.</p>
<p>In the pivotal double-blind, randomized study of cancer patients, where 38 subjects were administered epidural Duraclon at 30 mcg/hr in addition to epidural morphine, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> occurred in 45% of subjects. Most episodes of <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> occurred within the first four days after beginning epidural clonidine. However, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotensive episodes</span> occurred throughout the duration of the trial. There was a tendency for these episodes to occur more commonly in women, and in those with higher serum clonidine levels. Patients experiencing <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> also tended to weigh less than those who did not experience <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>. The <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> is usually responsive to intravenous fluids and, if necessary, appropriate parenterally-administered pressor agents.</p>
<p>Published reports on the use of epidural clonidine for intraoperative or postoperative <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> also show a consistent and marked hypotensive response to clonidine. Severe <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> may occur even if intravenous fluid pretreatment is given.</p>
<p><span class="Bold"><span class="Italics">Withdrawal</span></span></p>
<p>Sudden cessation of clonidine treatment, regardless of the route of administration, has, in some cases, resulted in symptoms such as <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, and <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, accompanied or followed by a rapid <span class="product-label-link" type="condition" conceptid="141693" conceptname="Elevated blood-pressure reading without diagnosis of hypertension">rise in blood pressure</span>. The likelihood of such reactions appears to be greater after administration of higher doses or with concomitant beta-blocker treatment. Special caution is therefore advised in these situations. Rare instances of <span class="product-label-link" type="condition" conceptid="312938" conceptname="Hypertensive encephalopathy">hypertensive encephalopathy</span>, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">cerebrovascular accidents</span> and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> have been reported after abrupt clonidine withdrawal. Patients with a history of <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> and/or other underlying cardiovascular conditions may be at particular risk of the consequences of abrupt discontinuation of clonidine. In the pivotal double-blind, randomized cancer <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> study, four of 38 subjects receiving 720 mcg of clonidine per day experienced <span class="product-label-link" type="condition" conceptid="4221991" conceptname="Rebound hypertension">rebound hypertension</span> following abrupt withdrawal. One of these patients with <span class="product-label-link" type="condition" conceptid="4221991" conceptname="Rebound hypertension">rebound hypertension</span> subsequently experienced a <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">cerebrovascular accident</span>.</p>
<p>Careful monitoring of infusion pump function and inspection of catheter tubing for obstruction or dislodgement can help reduce the risk of inadvertent abrupt withdrawal of epidural clonidine. Patients should notify their physician immediately if clonidine administration is inadvertently interrupted for any reason. Patients should also be instructed not to discontinue therapy without consulting their physician.</p>
<p>When discontinuing therapy with epidural clonidine, the physician should reduce the dose gradually over 2 to 4 days to avoid withdrawal symptoms.</p>
<p>An excessive <span class="product-label-link" type="condition" conceptid="141693" conceptname="Elevated blood-pressure reading without diagnosis of hypertension">rise in blood pressure</span> following discontinuation of epidural clonidine can be treated by administration of clonidine or by intravenous phentolamine. If therapy is to be discontinued in patients receiving a beta-blocker and clonidine concurrently, the beta-blocker should be withdrawn several days before the gradual discontinuation of epidural clonidine.</p>
<p><span class="Bold"><span class="Italics"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></span></span></p>
<p><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> related to implantable epidural catheters pose a serious risk. Evaluation of <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> in a patient receiving epidural clonidine should include the possibility of a catheter-related <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> such as <span class="product-label-link" type="condition" conceptid="435785" conceptname="Meningitis">meningitis</span> or <span class="product-label-link" type="condition" conceptid="4268039" conceptname="Epidural abscess">epidural abscess</span>.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="i4i_precautions_id_410888ca-e6e4-4306-82ef-1cca6ed059e3"></a><a name="section-6"></a><p></p>
<h1>PRECAUTIONS</h1>
<p class="First"><span class="Bold"><span class="Italics">General</span></span></p>
<p><span class="Underline">Cardiac Effects:</span> Epidural clonidine frequently causes decreases in heart rate. Symptomatic <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span> can be treated with atropine. Rarely, <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">atrioventricular block</span> greater than first degree has been reported. Clonidine does not alter the hemodynamic response to exercise, but may mask the increase in heart rate associated with <span class="product-label-link" type="condition" conceptid="436375" conceptname="Hypovolemia">hypovolemia</span>.</p>
<p><span class="Underline"><span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">Respiratory Depression</span> and Sedation:</span></p>
<p>Clonidine administration may result in sedation through the activation of alpha-adrenoceptors in the brainstem. High doses of clonidine cause sedation and ventilatory abnormalities that are usually mild. Tolerance to these effects can develop with chronic administration. These effects have been reported with bolus doses that are significantly larger than the infusion rate recommended for treating cancer <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>.</p>
<p><span class="Underline"><span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span>:</span> <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span> has been seen in a small percentage of patients treated with oral or transdermal clonidine. <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span> commonly occurs in cancer patients and may be exacerbated by treatment with clonidine. Patients, especially those with a known history of <span class="product-label-link" type="condition" conceptid="444100" conceptname="Mood disorder">affective disorders</span>, should be monitored for the signs and symptoms of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>.</p>
<p><span class="Underline"><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> of Visceral or Somatic Origin:</span> In the clinical investigations, at doses tested, Duraclon was most effective in well-localized, â€˜â€˜neuropathicâ€™â€™ <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> that was characterized as electrical, burning, or shooting in nature, and which was localized to a dermatomal or peripheral nerve distribution. Duraclon may be less effective, or possibly ineffective in the treatment of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> that is diffuse, poorly localized, or visceral in origin.</p>
<p><span class="Bold"><span class="Italics">Information for Patients</span></span></p>
<p>Patients should be instructed about the risks of <span class="product-label-link" type="condition" conceptid="4221991" conceptname="Rebound hypertension">rebound hypertension</span> and warned not to discontinue clonidine except under the supervision of a physician. Patients should notify their physician immediately if clonidine administration is inadvertently interrupted for any reason. Patients who engage in potentially hazardous activities, such as operating machinery or driving, should be advised of the potential sedative and hypotensive effects of epidural clonidine. They should also be informed that sedative effects may be increased by CNS-depressing drugs such as alcohol and barbiturates, and that hypotensive effects may be increased by opiates.</p>
<p><span class="Bold"><span class="Italics">Drug Interactions</span></span></p>
<p>Clonidine may potentiate the CNS-depressive effect of alcohol, barbiturates or other sedating drugs. Narcotic analgesics may potentiate the hypotensive effects of clonidine. Tricyclic anti-depressants may antagonize the hypotensive effects of clonidine. The effects of tricyclic anti-depressants on clonidineâ€™s analgesic actions are not known.</p>
<p>Beta-blockers may exacerbate the hypertensive response seen with clonidine withdrawal. Also, due to the potential for additive effects such as <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span> and <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">AV block</span>, caution is warranted in patients receiving clonidine with agents known to affect sinus node function or AV nodal conduction, e.g., digitalis, calcium channel blockers, and beta-blockers.</p>
<p>There is one reported case of a patient with <span class="product-label-link" type="condition" conceptid="373995" conceptname="Delirium">acute delirium</span> associated with the simultaneous use of fluphenazine and oral clonidine. Symptoms resolved when clonidine was withdrawn and recurred when the patient was rechallenged with clonidine.</p>
<p>Epidural clonidine may prolong the duration of pharmacologic effects of epidural local anesthetics, including both sensory and motor blockade.</p>
<p><span class="Bold"><span class="Italics">Carcinogenesis, Mutagenesis, Impairment of Fertility</span></span></p>
<p>In a 132-week study in rats, clonidine hydrochloride administered as a dietary admixture at 5-8 times (based on body surface area) the 50 mcg/kg maximum recommended daily human dose (MRDHD) for <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> did not show any carcinogenic potential. Clonidine was inactive in the Ames test of mutagenicity. Fertility of male or female rats was unaffected by oral clonidine hydrochloride doses as high as 150 mcg/kg, or about 0.5 times the MRDHD. Fertility of female rats did, however, appear to be affected in another experiment at oral dose levels of 500-2000 mcg/kg, or 2-7 times the MRDHD.</p>
<p><span class="Bold"><span class="Italics">Usage in Pregnancy/Teratogenic Effects</span></span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c2d7a218-0612-43bc-90b2-3ff90fcc4278"></a><a name="section-7"></a><p></p>
<h1>PREGNANCY CATEGORY C</h1>
<p class="First">Reproduction studies in rabbits at clonidine hydrochloride doses up to approximately the MRDHD revealed no evidence of teratogenic or embryotoxic potential. In rats, however, doses as low as one-third the MRDHD were associated with increased resorptions in a study in which dams were treated continuously from 2 months prior to mating. Increased resorptions were not associated with treatment with the same or higher doses up to 0.5 times the MRDHD when dams were treated on days 6-15 of gestation. Increased resorptions were observed at higher levels (7-times the MRDHD) in rats and mice treated on days 1-14 of gestation.</p>
<p>Clonidine readily crosses the placenta and its concentrations are equal in maternal and umbilical cord plasma; amniotic fluid concentrations can be 4-times those found in serum. There are no adequate and well-controlled studies in pregnant women during early gestation when organ formation takes place. Studies using epidural clonidine during labor have demonstrated no apparent adverse effects on the infant at the time of delivery. However, these studies did not monitor the infants for hemodynamic effects in the days following delivery. Clonidine hydrochloride injection should be used during pregnancy only if the potential benefits justify the potential risk to the fetus.</p>
<p><span class="Bold"><span class="Italics">Labor and Delivery</span></span></p>
<p>There are no adequate controlled clinical trials evaluating the safety, efficacy, and dosing of Duraclon in obstetrical settings. Because maternal perfusion of the placenta is critically dependent on blood pressure, use of Duraclon as an analgesic during labor and delivery is not indicated (see <span class="Bold"><a href="#i4i_warnings_id_369afbc8-7987-40f9-8113-29f28f9e09b7">WARNINGS</a></span>).</p>
<p><span class="Bold"><span class="Italics">Nursing Mothers</span></span></p>
<p>Concentrations of clonidine in human breast milk are approximately twice those found in maternal plasma. Caution should be exercised when clonidine is administered to a nursing woman. Because of the potential for severe adverse reactions in nursing infants, a decision should be made to either discontinue nursing or to discontinue clonidine.</p>
<p><span class="Bold"><span class="Italics">Pediatric Use</span></span></p>
<p>The safety and effectiveness of Duraclon in this limited indication and clinical population have been established in patients old enough to tolerate placement and management of an epidural catheter, based on evidence from adequate and well controlled studies in adults and experience with the use of clonidine in the pediatric age group for other indications. The use of Duraclon should be restricted to pediatric patients with severe <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">intractable pain</span> from malignancy that is unresponsive to epidural or spinal opiates or other more conventional analgesic techniques. The starting dose of Duraclon should be selected on per kilogram basis (0.5 mcg per kg per hour) and cautiously adjusted based on the clinical response.</p>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_3267816a-5399-4829-b99a-cdf1844a18bf"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">Adverse reactions seen during continuous epidural clonidine infusion are dose-dependent and typical for a compound of this pharmacologic class. The adverse events most frequently reported in the pivotal controlled clinical trial of continuous epidural clonidine administration consisted of <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">postural hypotension</span>, decreased heart rate, <span class="product-label-link" type="condition" conceptid="4221991" conceptname="Rebound hypertension">rebound hypertension</span>, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>. <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span> is the adverse event that most frequently requires treatment. The <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> is usually responsive to intravenous fluids and, if necessary, appropriate parenterally-administered pressor agents. <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span> was observed more frequently in women and in lower weight patients, but no dose-related response was established.</p>
<p>Implantable epidural catheters are associated with a risk of catheter-related <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, including <span class="product-label-link" type="condition" conceptid="435785" conceptname="Meningitis">meningitis</span> and/or <span class="product-label-link" type="condition" conceptid="4268039" conceptname="Epidural abscess">epidural abscess</span>. The risk depends on the clinical situation and the type of catheter used, but catheter related <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> occur in 5%-20% of patients, depending on the kind of catheter used, catheter placement technique, quality of catheter care, and length of catheter placement.</p>
<p>The inadvertent intrathecal administration of clonidine has not been associated with a significantly increased risk of adverse events, but there are inadequate safety and efficacy data to support the use of intrathecal clonidine.</p>
<p>Epidural clonidine was compared to placebo in a two week double-blind study of 85 terminal cancer patients with <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">intractable pain</span> receiving epidural morphine. The following adverse events were reported in two or more patients and may be related to administration of either Duraclon or morphine.</p>
<a name="_Refid_fcba3ec7-dc46-4c0f-82d2-a34a565a5"></a><table>
<caption><span>Incidence of Adverse Events in the Two-Week Trial</span></caption>
<col width="69%">
<col width="12%">
<col width="11%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="Bold">Adverse Events</span></p></td>
<td class="Botrule Rrule Toprule" align="center" valign="top">
<p class="First"><span class="Bold">Clonidine</span></p>
<p><span class="Bold">N = 38</span></p>
<p><span class="Bold">n (%)</span></p>
</td>
<td class="Botrule Rrule Toprule" align="center" valign="top">
<p class="First"><span class="Bold">Placebo</span></p>
<p><span class="Bold">N = 47</span></p>
<p><span class="Bold">n (%)</span></p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Total Number of Patients Who Experienced at Least One Adverse Event</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">37 (97.4)</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">38 (80.5)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">17 (44.8)</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">5 (10.6)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">Postural Hypotension</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">12 (31.6)</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">0 (0)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">Dry Mouth</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">5 (13.2)</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">4 (8.5)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">5 (13.2)</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">10 (21.3)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">5 (13.2)</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">10 (21.3)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">5 (13.2)</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">2 (4.3)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">Confusion</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">5 (13.2)</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">5 (10.6)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">4 (10.5)</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">7 (14.9)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span>/<span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">3 (7.9)</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">1 (2.1)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">Sweating</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">2 (5.3)</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">0 (0)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">Chest Pain</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">2 (5.3)</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">0 (0)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">Hallucination</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">2 (5.3)</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">1 (2.1)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">Tinnitus</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">2 (5.3)</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">0 (0)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">1 (2.6)</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">2 (4.3)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">Tachycardia</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">1 (2.6)</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">2 (4.3)</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="312603" conceptname="Hypoventilation">Hypoventilation</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">1 (2.6)</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">2 (4.3)</p></td>
</tr>
</tbody>
</table>
<p>An open label long-term extension of the above trial was performed. Thirty-two subjects received epidural clonidine and morphine for up to 94 weeks with a median dosing period of 10 weeks. The following adverse events (and percent incidence) were reported: <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>/<span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">postural hypotension</span> (47%); <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (13%); <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>/<span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span> (38%); <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> (25%); <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infection</span> (22%); <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> (6% each); <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, <span class="product-label-link" type="condition" conceptid="4031840" conceptname="Hyperesthesia">hyperaesthesia</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="4262920" conceptname="Skin ulcer">skin ulcer</span>, and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> (5% each). Eighteen percent of subjects discontinued this study as a result of catheter-related problems (<span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, accidental dislodging, etc.), and one subject developed <span class="product-label-link" type="condition" conceptid="435785" conceptname="Meningitis">meningitis</span>, possibly as a result of a catheter-related <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. In this study, <span class="product-label-link" type="condition" conceptid="4221991" conceptname="Rebound hypertension">rebound hypertension</span> was not assessed, and ECG and laboratory data were not systematically sought.</p>
<p>The following adverse reactions have also been reported with the use of any dosage form of clonidine. In many cases patients were receiving concomitant medication and a causal relationship has not been established:</p>
<p><span class="Bold">Body as a Whole:</span> <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Weakness</span>, 10%; <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, 4%; <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> and withdrawal syndrome, each 1%. Also reported were <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pallor</span>, a weakly positive Coombâ€™s test, and increased sensitivity to alcohol.</p>
<p><span class="Bold">Cardiovascular:</span> <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">Palpitations</span> and <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, and <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, each 0.5%. <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">Syncope</span>, Raynaudâ€™s phenomenon, <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, and electrocardiographic abnormalities (i.e., sinus node arrest, functional <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, high degree <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">AV block</span>) have been reported rarely. Rare cases of <span class="product-label-link" type="condition" conceptid="4171683" conceptname="Sinus bradycardia">sinus bradycardia</span> and <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">atrioventricular block</span> have been reported, both with and without the use of concomitant digitalis.</p>
<p><span class="Bold">Central Nervous System:</span> <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">Nervousness</span> and <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, 3%; mental <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, 1%; <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, 0.5%. <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Cerebrovascular accidents</span>, other behavioral changes, <span class="product-label-link" type="condition" conceptid="4304251" conceptname="Bizarre dreams">vivid dreams</span> or <span class="product-label-link" type="condition" conceptid="4009184" conceptname="Dream anxiety disorder">nightmares</span>, <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span>, and <span class="product-label-link" type="condition" conceptid="373995" conceptname="Delirium">delirium</span> have been reported rarely.</p>
<p><span class="Bold">Dermatological:</span> <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span>, 1%; <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, 0.7%; <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">hives</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioneurotic edema</span> and <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, 0.5%; <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>, 0.2%.</p>
<p><span class="Bold">Gastrointestinal:</span> <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Anorexia</span> and <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, each 1%; mild transient abnormalities in liver function tests, 1%; <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, <span class="product-label-link" type="condition" conceptid="4032796" conceptname="Parotitis">parotitis</span>, <span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">ileus</span> and pseudo obstruction, and <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, rarely.</p>
<p><span class="Bold">Genitourinary:</span> Decreased sexual activity, <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">impotence</span>, and libido, 3%; <span class="product-label-link" type="condition" conceptid="40304526" conceptname="Nocturia">nocturia</span>, about 1%; <span class="product-label-link" type="condition" conceptid="197684" conceptname="Dysuria">difficulty in micturition</span>, about 0.2%; <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span>, about 0.1%.</p>
<p><span class="Bold">Hematologic:</span> <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span>, rarely.</p>
<p><span class="Bold">Metabolic:</span> <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight gain</span>, 0.1%; <span class="product-label-link" type="condition" conceptid="4168447" conceptname="Gynecomastia">gynecomastia</span>, 1%; transient elevation of glucose or serum phosphatase, rarely.</p>
<p><span class="Bold">Musculoskeletal:</span> Muscle or <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">joint pain</span>, about 0.6%; <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">leg cramps</span>, 0.3%.</p>
<p><span class="Bold">Oro-otolaryngeal:</span> Dryness of the nasal mucosa was rarely reported.</p>
<p><span class="Bold">Ophthalmological:</span> Dryness of the eyes, burning of the eyes and <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span> were rarely reported.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_id_d191d9ab-0c60-47e7-9ecf-0dbfe4f6f7c1"></a><a name="section-9"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First"><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span> may develop early and may be followed by <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, <span class="product-label-link" type="condition" conceptid="435371" conceptname="Hypothermia">hypothermia</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, decreased or <span class="product-label-link" type="condition" conceptid="4290597" conceptname="Absent reflex">absent reflexes</span>, <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, and <span class="product-label-link" type="condition" conceptid="435279" conceptname="Tonic pupillary reaction">miosis</span>. With large oral <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdoses</span>, reversible cardiac conduction defects or <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span>, <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">apnea</span>, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>, and <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> have been reported. As little as 100 mcg of oral clonidine has produced signs of toxicity in pediatric patients.</p>
<p>There is no specific antidote for clonidine overdosage. Supportive care may include atropine sulfate for <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, intravenous fluids and/or vasopressor agents for <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>. <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span> associated with overdosage has been treated with intravenous furosemide, diazoxide or alpha-blocking agents such as phentolamine. Naloxone may be a useful adjunct in the treatment of clonidine induced <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, and/or <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>; blood pressure should be monitored since the administration of naloxone has occasionally resulted in paradoxical <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>. Tolazoline administration has yielded inconsistent results and is not recommended as first-line therapy. Dialysis is not likely to significantly enhance the elimination of clonidine.</p>
<p>The largest <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> reported to date involved a 28-year old white male who ingested 100 mg of clonidine hydrochloride powder. This patient developed <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> followed by <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">apnea</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, semi-<span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>, and <span class="product-label-link" type="condition" conceptid="4008580" conceptname="Ventricular bigeminy">premature ventricular contractions</span>. The patient fully recovered after intensive treatment. Plasma clonidine levels were 60 ng/mL after 1 hour, 190 ng/mL after 1.5 hours, 370 ng/mL after 2 hours, and 120 ng/mL after 5.5 and 6.5 hours. In mice and rats, the oral LD50 of clonidine is 206 and 465 mg/kg, respectively.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_93fa221d-9048-4302-957a-87a1eae8759a"></a><a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">The recommended starting dose of Duraclon for continuous epidural infusion is 30 mcg/hr. Although dosage may be titrated up or down depending on <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> relief and occurrence of adverse events, experience with dosage rates above 40 mcg/hr is limited.</p>
<p>Familiarization with the continuous epidural infusion device is essential. Patients receiving epidural clonidine from a continuous infusion device should be closely monitored for the first few days to assess their response. </p>
<p>The 500 mcg/mL (0.5 mg/mL) strength product must be diluted prior to use in 0.9% Sodium Chloride for Injection, U.S.P., to a final concentration of 100 mcg/mL: </p>
<table>
<col width="15%">
<col width="22%">
<col width="27%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<p class="First"><span class="Bold">Volume of</span></p>
<p><span class="Bold">Duraclon</span></p>
<p><span class="Bold">500 mcg/mL</span></p>
</td>
<td class="Botrule Rrule Toprule" align="center" valign="top">
<p class="First"><span class="Bold">Volume of 0.9%</span></p>
<p><span class="Bold">Sodium Chloride</span></p>
<p><span class="Bold">for Injection, U.S.P.</span></p>
</td>
<td class="Botrule Rrule Toprule" align="center" valign="top">
<p class="First"><span class="Bold">Resulting Final Duraclon</span></p>
<p><span class="Bold">Concentration</span></p>
<p><span class="Bold">(100 mcg/mL)</span></p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">1 mL</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">4 mL</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">500 mcg/5 mL</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">2 mL</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">8 mL</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">1000 mcg/10 mL</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">3 mL</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">12 mL</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">1500 mcg/15 mL</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">4 mL</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">16 mL</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">2000 mcg/20 mL</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">5 mL</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">20 mL</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">2500 mcg/25 mL</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">6 mL</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">24 mL</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">3000 mcg/30 mL</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">7 mL</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">28 mL</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">3500 mcg/35 mL</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">8 mL</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">32 mL</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">4000 mcg/40 mL</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">9 mL</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">36 mL</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">4500 mcg/45 mL</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">10 mL</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">40 mL</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">5000 mcg/50 mL</p></td>
</tr>
</tbody>
</table>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_1779a5e7-11a0-4f9f-9458-0badca43a74d"></a><a name="section-10.1"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">Dosage should be adjusted according to the degree of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, and patients should be carefully monitored. Since only a minimal amount of clonidine is removed during routine hemodialysis, there is no need to give supplemental clonidine following dialysis.</p>
<p>Duraclon must <span class="Italics">not</span> be used with a preservative.</p>
<p>Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_00f6ce7f-4557-4a6c-b35d-a787808dded4"></a><a name="section-11"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">NDC 67457-218-10, 100 mcg/mL solution in<br>10 mL vials, packaged individually.</p>
<p>NDC 67457-219-10, 500 mcg/mL solution in<br>10 mL vials, packaged individually.</p>
<p><span class="Bold">Store at 20Â° to 25Â°C (68Â° to 77Â°F). [See USP Controlled Room Temperature.]</span></p>
<p><span class="Bold">Preservative Free.</span> Discard unused portion.</p>
<p>Duraclon<span class="Sup">Â®</span> is a licensed registered trademark.</p>
<p>Manufactured for:<br><span class="Bold">Mylan Institutional LLC</span><br>Rockford, IL 61103 U.S.A.</p>
<p>Manufactured by:<br><span class="Bold">Mylan Institutional</span><br>Galway, Ireland</p>
<p>0764L102<br>REVISED JUNE 2012<br>MI:DURAIJ:R2</p>
<p>To request medical information or to report suspected adverse reactions, contact Drug Safety at 1-877-446-3679 (1-877-4-INFO-RX) or FDA at 1-800-FDA-1088 or <span class="Italics">www.fda.gov/medwatch</span></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_b1c829f6-642f-4025-8f2a-cf25adc4d9f9"></a><a name="section-12"></a><p></p>
<h1>Â Â Â Â Â Â Â </h1>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL </span></p>
<p><span class="Bold">NDC 67457-218-10 10 mL</span></p>
<p><span class="Bold">DuraclonÂ®</span><br><span class="Bold">clonidine HCl</span><br><span class="Bold">injection</span></p>
<p><span class="Bold">1000 mcg/10 mL</span><br><span class="Bold">(100 mcg/mL)</span></p>
<p><span class="Bold">For Epidural Injection</span></p>
<p><span class="Bold">Rx only Single-Dose Vial</span></p>
<p><span class="Bold">Preservative Free</span></p>
<p>Sterile. Non-pyrogenic.</p>
<p><span class="Bold">Each mL contains:</span> 100 mcg<br>clonidine hydrochloride, USP<br>and 9 mg sodium chloride, USP<br>in water for injection, USP.</p>
<p>Hydrochloric acid and/or sodium<br>hydroxide may have been added<br>for pH adjustment. Discard<br>unused portion.</p>
<p><span class="Bold">Usual Dosage:</span> See<br>accompanying prescribing<br>information.</p>
<p><span class="Bold">Store at 20Â° to 25Â°C (68Â° to</span><br><span class="Bold">77Â°F). [See USP Controlled</span><br><span class="Bold">Room Temperature.]</span></p>
<p>Manufactured for:<br><span class="Bold">Mylan Institutional LLC</span><br>Rockford, IL 61103 U.S.A.<br>Made in Ireland<br>0414C101 Â Â Â Â Â Â Â Â Â Â Â MI:218:1C:R2</p>
<p>DuraclonÂ® is a licensed registered trademark.</p>
<p><span class="Bold">Mylan.com</span></p>
<div class="Figure">
<a name="id783"></a><img alt="Duraclon Clonidine HCI Injection 1000 mcg/10 mL Carton Labels" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=8c126bb8-732a-4949-8754-2f50b5543638&amp;name=e3b05939-069f-4822-8694-b693a044adb3-02.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_e1826dc3-7c8a-419a-ad66-077e3c638fea"></a><a name="section-13"></a><p></p>
<h1>Â Â Â Â Â </h1>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL </span></p>
<p><span class="Bold">NDC 67457-219-10 10 mL</span></p>
<p><span class="Bold">DuraclonÂ®</span><br><span class="Bold">clonidine HCl</span><br><span class="Bold">injection</span></p>
<p><span class="Bold">5000 mcg/10 mL</span><br><span class="Bold">(500 mcg/mL)</span></p>
<p><span class="Bold">For Epidural Injection</span><br><span class="Bold">MUST BE DILUTED</span><br><span class="Bold">BEFORE USE</span></p>
<p><span class="Bold">Rx only Single-Dose Vial</span></p>
<p><span class="Bold">Preservative Free</span></p>
<p>Sterile. Non-pyrogenic.</p>
<p><span class="Bold">Each mL contains:</span> 500 mcg<br>clonidine hydrochloride, USP<br>and 9 mg sodium chloride, USP<br>in water for injection, USP.</p>
<p>Hydrochloric acid and/or sodium<br>hydroxide may have been added<br>for pH adjustment. Discard<br>unused portion.</p>
<p><span class="Bold">Usual Dosage: </span>See<br>accompanying prescribing<br>information.</p>
<p><span class="Bold">Store at 20Â° to 25Â°C (68Â° to</span><br><span class="Bold">77Â°F). [See USP Controlled</span><br><span class="Bold">Room Temperature.]</span></p>
<p>Manufactured for:<br><span class="Bold">Mylan Institutional LLC</span><br>Rockford, IL 61103 U.S.A.<br>Made in Ireland<br>0413C101 Â Â Â Â Â Â Â Â Â Â Â MI:219:1C:R2</p>
<p>DuraclonÂ® is a licensed registered trademark.</p>
<p><span class="Bold">Mylan.com</span></p>
<div class="Figure">
<a name="id843"></a><img alt="Duraclon Clonidine HCI Injection 5000 mcg/10 mL Carton Labels" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=8c126bb8-732a-4949-8754-2f50b5543638&amp;name=e3b05939-069f-4822-8694-b693a044adb3-03.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>DURACLONÂ 		
					</strong><br><span class="contentTableReg">clonidine hydrochloride injection, solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:67457-218</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">EPIDURAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>CLONIDINE HYDROCHLORIDE</strong> (CLONIDINE) </td>
<td class="formItem">CLONIDINE HYDROCHLORIDE</td>
<td class="formItem">0.1Â mg Â inÂ 1Â mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM CHLORIDE</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:67457-218-10</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">10 mL in 1 VIAL</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA020615</td>
<td class="formItem">10/02/1996</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>DURACLONÂ 		
					</strong><br><span class="contentTableReg">clonidine hydrochloride injection, solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:67457-219</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">EPIDURAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>CLONIDINE HYDROCHLORIDE</strong> (CLONIDINE) </td>
<td class="formItem">CLONIDINE HYDROCHLORIDE</td>
<td class="formItem">0.5Â mg Â inÂ 1Â mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM CHLORIDE</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:67457-219-10</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">10 mL in 1 VIAL</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA020615</td>
<td class="formItem">10/02/1996</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Mylan Institutional LLC
							(790384502)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 6/2012<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>e3b05939-069f-4822-8694-b693a044adb3</div>
<div>Set id: 8c126bb8-732a-4949-8754-2f50b5543638</div>
<div>Version: 3</div>
<div>Effective Time: 20120629</div>
</div>
</div>Â <div class="DistributorName">Mylan Institutional LLC</div></p>
</body></html>
